Sciclone Pharmaceuticals Inc. has wound down a strategic review process after having spoken with a number of potential buyers, deciding instead to remain a publicly listed company. The company said the board did not receive a bid that reflected a premium to the company's trading price. Sciclone plans to continue with growth plans for its China-focused commercial business.